Atopic Dermatitis Clinical Trial
— VahvistuOfficial title:
Nationwide Research on the Rewilding of Kindergarten Yards - Vahvistu
NCT number | NCT06390878 |
Other study ID # | R24023 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2024 |
Est. completion date | August 30, 2027 |
Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children. The investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children. Our specific aims are: To assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms. Assess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).
Status | Recruiting |
Enrollment | 320 |
Est. completion date | August 30, 2027 |
Est. primary completion date | August 30, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 5 Years |
Eligibility | Inclusion Criteria: - Attendance in kindergarten Exclusion Criteria: - Use of antibiotics in the year before sampling |
Country | Name | City | State |
---|---|---|---|
Finland | Natural Resources Institute Finland | Helsinki | Uusimaa |
Finland | Tampere University | Tampere |
Lead Sponsor | Collaborator |
---|---|
Natural Resources Institute Finland | Tampere University |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Associations between environmental factors and primary and secondary outcomes. | Associations between environmental factors (vegetation, deadwood, and polypore richness, land cover categories and other yard characteristics) and cytokine levels, microbial measurements, white blood cell transcriptome and distribution, cortisol levels, cognitive skills, the prevalence of infectious diseases and atopy, allergy and asthma symptoms. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Primary | Skin Gammaproteobacteria | Difference on skin gammaproteobacterial diversity between rewilding and control group | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Cortisol levels | Cortisol levels measured from hair samples | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Difference in diversity of skin, saliva and stool microbiota | It will be analyzed if microbial communities are different between treatments | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Difference in observed species richness of skin, saliva and stool microbiota | It will be analyzed if microbial communities are different between treatments | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Difference in taxonomies of skin, saliva and stool microbiota | It will be analyzed if microbial communities are different between treatments | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Distribution of white blood cells | It will be analyzed if the distribution is different between treatments | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | White blood cell transcriptomics | White blood cell transcriptome is analyzed with single cell RNA sequencing. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Plasma cytokines | Cytokines will be analyzed analyzed with Meso Scale. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Skin cytokines | Cytokines will be analyzed using skin tape strip samples. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Infectious diseases | Infections will be recorded with questionnaires. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Asthma symptoms | Asthma symptoms will be recorded with questionnaires. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Atopic dermatitis | Atopic dermatitis will be recorded with questionnaires. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Allergy | Allergies will be recorded with questionnaires. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Patient-oriented Eczema Measure | Lower score on patient-oriented Eczema Measure among intervention treatment compared to control that indicates lower eczema among intervention treatment. Minimum 0, maximum 28. | Baseline, 3 month, 1 year, 2 year, 3 year | |
Secondary | Wechsler Preschool and Primary Scale of Intelligence | Higher score on Wechsler Preschool and Primary Scale of Intelligence among intervention treatment compared to control that indicates better cognitive skills among intervention treatment. Minimum 40, maximum 170. | Baseline, 3 month, 1 year, 2 year, 3 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |